WKA
RMD icon

Wilson Kemp & Associates’s ResMed RMD Stock Holding History

Wilson Kemp & Associates’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-7,700
Closed -$348K – 80
2013
Q2 		$348K Buy
+7,700
New +$365K 0.33% 71

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
LCG
Luxor Capital Group New York $1.43B AUM 30.88% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Wilson Kemp & Associates's RMD Position: Q3 2013 in Review

Wilson Kemp & Associates sold out of ResMed (RMD) in Q3 2013, closing a stake of 7,700 shares — an estimated $348K sold.

Wilson Kemp & Associates first reported a position in RMD in Q2 2013 and held it in 1 quarter. The position peaked at $348K in Q2 2013. 322 funds tracked by Wall St. Rank hold RMD as of Q3 2013.

  • Wilson Kemp & Associates reported no remaining ResMed position as of Q3 2013 after selling out during the quarter.
  • Wilson Kemp & Associates sold 7,700 ResMed shares in Q3 2013, an estimated $348K.
  • Wilson Kemp & Associates first reported a position in ResMed in Q2 2013 and held it in 1 quarter.
  • Wilson Kemp & Associates's ResMed position peaked at $348K in Q2 2013.
  • 322 funds tracked by Wall St. Rank held ResMed as of Q3 2013.

Based on Wilson Kemp & Associates's 13F filing for Q3 2013, filed 21 Oct 2013.